The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether certain anti-HIV drugs (efavirenz [EFV] and
nelfinavir [NFV]) affect the amount of certain fat-lowering drugs (atorvastatin, pravastatin,
and simvastatin) in the blood.
Protease inhibitors (PIs), a type of anti-HIV drug, are known to cause increased lipids
(fats) in the blood of HIV-infected patients. EFV also is known to increase blood fats.
HIV-infected patients who take PIs and/or EFV may need to take fat-lowering drugs to correct
this problem. So it is important to look at possible drug interactions when these drugs are
taken together. This study will see if taking EFV or NFV, a protease inhibitor, affects the
blood level of simvastatin, atorvastatin, or pravastatin (all fat-lowering drugs). To obtain
results more quickly, the study population will be healthy HIV-negative volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)